GreenLight Biosciences Holdings (NASDAQ: GRNA) has completed its merger with SW MergerCo and SW ParentCo, with GreenLight surviving as a wholly-owned subsidiary of Parent. As a result, GreenLight common stock and warrants ceased trading on NASDAQ. Remaining shares of GreenLight common stock not purchased in the Offer will be converted into the right to receive $0.30 in cash. Concurrently, GreenLight secured $52.075 million in financing from investors led by Fall Line Capital. The combined company, now known as GreenLight Biosciences, will continue under the leadership of CEO Andrey J. Zarur, Ph.D.
GreenLight Biosciences Holdings, PBC (NASDAQ: GRNA) (“GreenLight” or the “Company”) today announced the closing of its previously announced merger with SW MergerCo, Inc. (“Merger Sub”) and SW ParentCo, Inc. (“Parent”), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the “Merger”). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the “NASDAQ”) before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each remaining share of GreenLight common stock not purchased in the Offer (other than shares of GreenLight common stock (i) owned by GreenLight as treasury stock, (ii) owned by Merger Sub immediately before the effective time of the Merger, (iii) that were irrevocably accepted by Merger Sub in the Offer, (iv) held by stockholders who have perfected their statutory rights of appraisal under Section 262 of the DGCL or (v) that are subject to the Contribution and Exchange Agreements entered into between Parent and certain stockholders of GreenLight) will be converted into the right to receive $0.30 in cash, without interest, and subject to deduction for any required withholding taxes.
Concurrent with the closing of the Merger, GreenLight completed its previously announced financing of $52.075 million from a syndicate of investors led by Fall Line Capital, LLC (“Fall Line”), of which $15 million had been previously funded in exchange for the issuance of $15 million of unsecured notes. The merger and concurrent financing positions GreenLight for increased efficiency and nimbleness to adapt to changing market opportunities.
The combined company will operate as GreenLight Biosciences and continue to be led by Andrey J. Zarur, Ph.D., the Company’s CEO and President prior to the Merger, and certain other members of the GreenLight management team.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“This merger and financing empowers GreenLight to operate with enhanced efficiency, advancing us closer to our mission of fostering healthy people and planet.” said Zarur. “We are excited to embark on this next chapter, leveraging the synergies created, as we pursue our goal of delivering market-leading RNA solutions.”
Advisors
Goodwin Procter LLP served as legal counsel to the Company. Roth Capital Partners, LLC served as financial advisor and Foley Hoag LLP served as legal counsel to the Special Committee. O’Melveny & Myers LLP served as legal counsel to Fall Line.
Source: BioSpace